DE60038869D1 - Hgf zur gentherapie der karidomyopathie - Google Patents

Hgf zur gentherapie der karidomyopathie

Info

Publication number
DE60038869D1
DE60038869D1 DE60038869T DE60038869T DE60038869D1 DE 60038869 D1 DE60038869 D1 DE 60038869D1 DE 60038869 T DE60038869 T DE 60038869T DE 60038869 T DE60038869 T DE 60038869T DE 60038869 D1 DE60038869 D1 DE 60038869D1
Authority
DE
Germany
Prior art keywords
hgf
caridomyopathy
gene therapy
cardiac muscle
cardiac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60038869T
Other languages
English (en)
Inventor
Ryuichi Morishita
Yoshiaki Taniyama
Toshio Ogihara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anges Inc
Original Assignee
Anges MG Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges MG Inc filed Critical Anges MG Inc
Application granted granted Critical
Publication of DE60038869D1 publication Critical patent/DE60038869D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60038869T 1999-10-08 2000-10-05 Hgf zur gentherapie der karidomyopathie Expired - Lifetime DE60038869D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP28853299 1999-10-08
PCT/JP2000/006947 WO2001026694A1 (fr) 1999-10-08 2000-10-05 Therapie genique pour cardiomyopathie

Publications (1)

Publication Number Publication Date
DE60038869D1 true DE60038869D1 (de) 2008-06-26

Family

ID=17731468

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60038869T Expired - Lifetime DE60038869D1 (de) 1999-10-08 2000-10-05 Hgf zur gentherapie der karidomyopathie

Country Status (10)

Country Link
US (1) US6989374B1 (de)
EP (1) EP1136083B1 (de)
JP (1) JP3865632B2 (de)
KR (1) KR20010093804A (de)
CN (2) CN101085363A (de)
AT (1) ATE395087T1 (de)
AU (1) AU775965B2 (de)
CA (1) CA2354029C (de)
DE (1) DE60038869D1 (de)
WO (1) WO2001026694A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69634567T2 (de) * 1995-08-29 2006-02-16 Anges Mg Inc., Toyonaka Ein medikament,das hgf gen enthält
CN1182874C (zh) * 1999-10-29 2005-01-05 安增子摩祺株式会社 糖尿病性局部缺血疾病的基因治疗制剂
JP2005097118A (ja) * 2000-07-18 2005-04-14 Yoshiki Sawa Ｈｇｆ遺伝子からなる細胞移植定着促進剤
US7862810B2 (en) 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US20020098167A1 (en) 2000-07-31 2002-07-25 Piero Anversa Methods and compositions for the repair and/or regeneration of damaged myocardium
US7547674B2 (en) * 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
EP1391214A4 (de) 2001-05-09 2006-05-17 Anges Mg Inc Gentransfer des angiogenen faktors bei hauterkrankungen
EP1435977A4 (de) * 2001-09-19 2005-06-08 Ford Henry Health System Herztransplantation von stammzellen zur behandlung von herzinsuffizienz
AU2002349583B2 (en) 2001-11-28 2007-11-22 Anges Mg, Inc. Genetic remedies for neurodegenerative diseases
US20080213348A1 (en) * 2002-06-06 2008-09-04 Anges Mg, Inc. Agents for gene therapy of cerebrovascular disorders
CN1703248A (zh) * 2002-10-02 2005-11-30 安琪士摩奇株式会社 用于听觉损害的药物制剂
US20070010436A1 (en) * 2003-04-01 2007-01-11 Yasuhiko Tabata Remedy for cardiomyopathy
WO2006046766A1 (ja) * 2004-10-29 2006-05-04 Anges Mg, Inc. 心不全治療のための遺伝子治療
US7696170B2 (en) 2005-01-24 2010-04-13 Kringle Pharma Inc. Fibrosis inhibitor for implanted organ
US8119123B2 (en) 2006-02-16 2012-02-21 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
CN101200721B (zh) * 2006-09-18 2011-06-08 复旦大学附属中山医院 人心肌保护基因及其用途
AU2008323719B2 (en) 2007-11-09 2013-04-04 New York Medical College Methods for the repair and/or regeneration of damaged myocardium using variants of hepatocyte growth factor
US8124071B2 (en) 2007-11-30 2012-02-28 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof
WO2010052828A1 (ja) * 2008-11-06 2010-05-14 国立大学法人名古屋大学 非虚血性心筋障害に対する医薬

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0452457T3 (da) 1989-11-03 1998-03-02 Univ Vanderbilt Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener
EP0461560B1 (de) 1990-06-11 1998-11-18 Toshikazu Nakamura Rekombinanter menschlicher Hepatozytwachstumsfaktor und Verfahren zu seiner Herstellung
JP2777678B2 (ja) 1990-06-11 1998-07-23 敏一 中村 組換ヒト肝実質細胞増殖因子及びその製造方法
US5652225A (en) 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
AU5189496A (en) * 1995-03-30 1996-10-16 Heartport, Inc. Endovascular cardiac venting catheter and method
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
DE69634567T2 (de) * 1995-08-29 2006-02-16 Anges Mg Inc., Toyonaka Ein medikament,das hgf gen enthält
US6121246A (en) 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
WO1999036103A1 (en) 1998-01-16 1999-07-22 Mcgill University Prevention and treatment of neuropathy by hepatocyte growth factor
ATE468863T1 (de) 1999-09-21 2010-06-15 Anges Mg Inc Gentherapie für zerebrale gefässerkrankungen
CN1182874C (zh) 1999-10-29 2005-01-05 安增子摩祺株式会社 糖尿病性局部缺血疾病的基因治疗制剂
CA2490357A1 (en) 2002-06-06 2003-12-18 Anges Mg, Inc. Gene therapeutic for cerebrovascular disorders

Also Published As

Publication number Publication date
EP1136083B1 (de) 2008-05-14
CN1293922C (zh) 2007-01-10
WO2001026694A1 (fr) 2001-04-19
CN1337884A (zh) 2002-02-27
ATE395087T1 (de) 2008-05-15
AU7556900A (en) 2001-04-23
KR20010093804A (ko) 2001-10-29
AU775965B2 (en) 2004-08-19
CN101085363A (zh) 2007-12-12
EP1136083A4 (de) 2005-11-16
EP1136083A1 (de) 2001-09-26
CA2354029A1 (en) 2001-04-19
JP3865632B2 (ja) 2007-01-10
US6989374B1 (en) 2006-01-24
CA2354029C (en) 2012-01-10

Similar Documents

Publication Publication Date Title
ATE395087T1 (de) Hgf zur gentherapie der karidomyopathie
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
WO2000054813A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
FI961755A0 (fi) Yhdistelmäadenovirusvektori ja menetelmiä sen käyttämiseksi
PL339735A1 (en) Pappiloma virus capsomer vaccine compositions and methods of applying them
CY1106733T1 (el) Αγωγη νευρολογικης δυσλειτουργιας περιλαμβανουσα σουλφαμικες φρουκτοπυρανοζες και ερυθροποιητινη
DE69939553D1 (de) Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
CY1106133T1 (el) Αγωνιστες υποδοχεα 2 παραγοντα απελευθερωσης κορτικοτροπινης
WO2002100390A3 (en) Improved method of treating the syndrome of coronary heart disease risk factors in humans
HK1014497A1 (en) Therapeutic uses of bactericidal/permeability increasing protein products
NO20005884D0 (no) Kombinasjonsterapi for behandling av bipolare forstyrrelser
ATE232396T1 (de) Oxydiertes thymosin beta 4
CY1112957T1 (el) Μη νευροτοξικοι παραγοντες, οι οποιοι ενεργοποιουν το πλασμινογονο για τη θεραπευτικη αγωγη εγκεφαλικου επεισοδιου
MXPA04005053A (es) Metodos y composiciones para tratar lesiones del epitelio respiratorio.
CY1108667T1 (el) Ανασυνδυασμενοι φορεις ιου περιεχοντες το ανθρωπινο γονιδιο του ενεργοποιητη πλασμινογονου ουροκινασης και η χρηση τους στην αγωγη της ινωσεως του ηπατος.
WO2000040273A3 (en) Treatment of viral diseases using an interferon omega expressing polynucleotide
ATE296894T1 (de) Genverabreichende vektoren mit gewebetropismus für glatte muskelzellen und/oder endothelzellen
DK1790655T3 (da) Biologisk aktive peptider
DE60019104D1 (de) Gentherapy von lungenkrankheiten
WO2000017375A3 (en) Method to treat haemophilia by in vivo gene therapy with retroviral vectors
ATE248920T1 (de) Rekombinatie viren,ihre herstellung und ihre verwendung in der gentherapie
AU2001268108A1 (en) Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
PT1103270E (pt) Tratamento de doencas auto-imunes em mamiferos
WO2001019850A3 (en) Nrage nucleic acids and polypeptides and uses thereof
FI20002612A0 (fi) Yhdistelmäterapia serotoniinivälityksen häiriöiden hoitamiseksi

Legal Events

Date Code Title Description
8364 No opposition during term of opposition